BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Women's health
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 14, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» Bioversys describes new rifabutin analogues for bacterial and
M. abscessus
infections
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Infection
Bioversys describes new rifabutin analogues for bacterial and
M. abscessus
infections
Sep. 3, 2024
No Comments
Bioversys AG has identified rifabutin analogues reported to be useful for the treatment of bacterial and
Mycobacterium abscessus
infections.
BioWorld Science
Infection
Patents
